BACKGROUND: Clinical trials in children with moderate-to-severe persistent asthma are limited. OBJECTIVE: We sought to determine whether azithromycin or montelukast are inhaled corticosteroid sparing. METHODS: The budesonide dose (with salmeterol [50 microg] twice daily) necessary to achieve control was determined in children 6 to 17 years of age with moderate-to-severe persistent asthma. After a budesonide-stable period of 6 weeks, children were randomized in a double-masked, parallel, multicenter study to receive once-nightly azithromycin, montelukast, or matching placebos plus the established controlling dose of budesonide (minimum, 400 microg twice daily) and salmeterol twice daily. Primary outcome was time from randomization to inadequate asthma control after sequential budesonide dose reduction. RESULTS: Of 292 children screened, only 55 were randomized. Inadequate adherence to study medication (n = 80) and improved asthma control under close medical supervision (n = 49) were the major reasons for randomization failure. A futility analysis was requested by the Data Safety Monitoring Board. In data available for analyses, no differences were noted for either treatment compared with placebo in time to inadequate control status (median: azithromycin, 8.4 weeks [95% confidence limit, 4.3-17.3]; montelukast, 13.9 weeks [95% confidence limit, 4.7-20.6]; placebo, 19.1 weeks [95% confidence limit, 11.7-infinity]), with no difference between the groups (log-rank test, P = .49). The futility analysis indicated that even if the planned sample size was reached, the results of this negative study were unlikely to be different, and the trial was prematurely terminated. CONCLUSION: Based on these results, neither azithromycin nor montelukast is likely to be an effective inhaled corticosteroid-sparing alternative in children with moderate-to-severe persistent asthma.
RCT Entities:
BACKGROUND: Clinical trials in children with moderate-to-severe persistent asthma are limited. OBJECTIVE: We sought to determine whether azithromycin or montelukast are inhaled corticosteroid sparing. METHODS: The budesonide dose (with salmeterol [50 microg] twice daily) necessary to achieve control was determined in children 6 to 17 years of age with moderate-to-severe persistent asthma. After a budesonide-stable period of 6 weeks, children were randomized in a double-masked, parallel, multicenter study to receive once-nightly azithromycin, montelukast, or matching placebos plus the established controlling dose of budesonide (minimum, 400 microg twice daily) and salmeterol twice daily. Primary outcome was time from randomization to inadequate asthma control after sequential budesonide dose reduction. RESULTS: Of 292 children screened, only 55 were randomized. Inadequate adherence to study medication (n = 80) and improved asthma control under close medical supervision (n = 49) were the major reasons for randomization failure. A futility analysis was requested by the Data Safety Monitoring Board. In data available for analyses, no differences were noted for either treatment compared with placebo in time to inadequate control status (median: azithromycin, 8.4 weeks [95% confidence limit, 4.3-17.3]; montelukast, 13.9 weeks [95% confidence limit, 4.7-20.6]; placebo, 19.1 weeks [95% confidence limit, 11.7-infinity]), with no difference between the groups (log-rank test, P = .49). The futility analysis indicated that even if the planned sample size was reached, the results of this negative study were unlikely to be different, and the trial was prematurely terminated. CONCLUSION: Based on these results, neither azithromycin nor montelukast is likely to be an effective inhaled corticosteroid-sparing alternative in children with moderate-to-severe persistent asthma.
Authors: P N Black; F Blasi; C R Jenkins; R Scicchitano; G D Mills; A R Rubinfeld; R E Ruffin; P R Mullins; J Dangain; B C Cooper; D B David; L Allegra Journal: Am J Respir Crit Care Med Date: 2001-08-15 Impact factor: 21.405
Authors: R F Lemanske; C A Sorkness; E A Mauger; S C Lazarus; H A Boushey; J V Fahy; J M Drazen; V M Chinchilli; T Craig; J E Fish; J G Ford; E Israel; M Kraft; R J Martin; S A Nachman; S P Peters; J D Spahn; S J Szefler Journal: JAMA Date: 2001 May 23-30 Impact factor: 56.272
Authors: Neil W Johnston; Piush J Mandhane; Jennifer Dai; Joanne M Duncan; Justina M Greene; Kim Lambert; Malcolm R Sears Journal: Pediatrics Date: 2007-09 Impact factor: 7.124
Authors: Lisa Saiman; Bruce C Marshall; Nicole Mayer-Hamblett; Jane L Burns; Alexandra L Quittner; Debra A Cibene; Sarah Coquillette; Ann Yunker Fieberg; Frank J Accurso; Preston W Campbell Journal: JAMA Date: 2003-10-01 Impact factor: 56.272
Authors: M J Visser; E van der Veer; D S Postma; L R Arends; T W de Vries; P L P Brand; E J Duiverman Journal: Eur Respir J Date: 2004-09 Impact factor: 16.671
Authors: E Kostadima; S Tsiodras; E I Alexopoulos; A G Kaditis; I Mavrou; N Georgatou; A Papamichalopoulos Journal: Eur Respir J Date: 2004-05 Impact factor: 16.671
Authors: Albert M Levin; Rasika A Mathias; Lili Huang; Lindsey A Roth; Denise Daley; Rachel A Myers; Blanca E Himes; Isabelle Romieu; Mao Yang; Celeste Eng; Julie E Park; Karla Zoratti; Christopher R Gignoux; Dara G Torgerson; Joshua M Galanter; Scott Huntsman; Elizabeth A Nguyen; Allan B Becker; Moira Chan-Yeung; Anita L Kozyrskyj; Pui-Yan Kwok; Frank D Gilliland; W James Gauderman; Eugene R Bleecker; Benjamin A Raby; Deborah A Meyers; Stephanie J London; Fernando D Martinez; Scott T Weiss; Esteban G Burchard; Dan L Nicolae; Carole Ober; Kathleen C Barnes; L Keoki Williams Journal: J Allergy Clin Immunol Date: 2012-11-10 Impact factor: 10.793
Authors: Stephen J Teach; Michelle A Gill; Alkis Togias; Christine A Sorkness; Samuel J Arbes; Agustin Calatroni; Jeremy J Wildfire; Peter J Gergen; Robyn T Cohen; Jacqueline A Pongracic; Carolyn M Kercsmar; Gurjit K Khurana Hershey; Rebecca S Gruchalla; Andrew H Liu; Edward M Zoratti; Meyer Kattan; Kristine A Grindle; James E Gern; William W Busse; Stanley J Szefler Journal: J Allergy Clin Immunol Date: 2015-10-27 Impact factor: 10.793
Authors: Anne Fuhlbrigge; David Peden; Andrea J Apter; Homer A Boushey; Carlos A Camargo; James Gern; Peter W Heymann; Fernando D Martinez; David Mauger; William G Teague; Carol Blaisdell Journal: J Allergy Clin Immunol Date: 2012-03 Impact factor: 10.793
Authors: K Takeda; Y Shiraishi; S Matsubara; N Miyahara; H Matsuda; M Okamoto; A Joetham; E W Gelfand Journal: Br J Pharmacol Date: 2010-07 Impact factor: 8.739
Authors: Michael Miligkos; Raveendhara R Bannuru; Hadeel Alkofide; Sucharita R Kher; Christopher H Schmid; Ethan M Balk Journal: Ann Intern Med Date: 2015-09-22 Impact factor: 25.391